Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN

Evommune, Inc. (NYSE:EVMN) Receives Average Rating of “Moderate Buy” from Analysts

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune's Stock Surges On Strong Results For New Eczema Drug

Evommune Nearly Doubles — Has Dupixent Met Its Match In Eczema?

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Buy” by Analysts

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

Evommune (NYSE:EVMN) Director Robert Lorne Hopfner Purchases 1,000 Shares

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering